Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 127Lymphoid 103Myeloid 63Plasma cell 45CNS 16Classical hematology 9Genitourinary 7Sarcoma 6Breast 6Dermatologic 3Gynecologic 2Gastrointestinal 2Other solid neoplasm 1Other neoplasm 1Endocrine 1

Conditions

Pheochromocytoma 1Neuroblastoma 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stem Cell Transplantation × Endocrine × Clear all
NCT01850888 2025-12-18

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Masonic Cancer Center, University of Minnesota

Phase NA Completed
15 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡